Literature DB >> 9124841

Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes.

H Rangel1, F Dagger, A Hernandez, A Liendo, J A Urbina.   

Abstract

Leishmania braziliensis (isolate 2903) was naturally resistant to ketoconazole or the bis-triazole D0870, inhibitors of sterol C-14 demethylase, which produced only moderate effects on the proliferation of promastigotes at 10 microM. In contrast, Leishmania mexicana (isolate NR) was extremely susceptible to the azoles, as complete growth arrest and cell lysis were induced by incubation of the parasites with 0.05 microM concentrations of the drugs for 72 h. The opposite response was observed with terbinafine, an inhibitor of squalene epoxidase: L. braziliensis 2903 was three times more susceptible to the drug than L. mexicana NR (MICs of 5 and 15 microM, respectively). However, when the L. braziliensis stock was grown in the presence of 1 microM terbinafine, which by itself produced only marginal (< 10%) effects on growth, it became highly susceptible to the azoles, with an MIC of 0.03 microM. Analysis of cellular free sterols by high-resolution capillary gas chromatography coupled to mass spectrometry showed that 14-methyl sterols can support normal growth of L. braziliensis 2903 but not of L. mexicana NR. On the other hand, the higher susceptibility of the L. braziliensis isolate to terbinafine was correlated with a massive accumulation of squalene in the presence of the allylamine while no significant effects on L. mexicana sterol composition were observed at drug concentrations up to 1 microM. Thus, the > 300-fold increase in the susceptibility of L. braziliensis promastigotes to azoles in the presence of terbinafine was attributed to the combined effect of squalene and the methylated sterol precursors on the physical properties of the cell's membranes, leading to the loss of cell viability. Combination therapy with azoles and terbinafine in the treatment of human L. braziliensis infections deserves further study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124841      PMCID: PMC163622     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

Review 1.  Recent developments in the chemotherapy of leishmaniasis.

Authors:  S L Croft
Journal:  Trends Pharmacol Sci       Date:  1988-10       Impact factor: 14.819

2.  Efficacy of ketoconazole in cutaneous leishmaniasis.

Authors:  L Weinrauch; R Livshin; Z Even-Paz; J El-On
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

3.  Sterols of Leishmania species. Implications for biosynthesis.

Authors:  L J Goad; G G Holz; D H Beach
Journal:  Mol Biochem Parasitol       Date:  1984-02       Impact factor: 1.759

4.  Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease.

Authors:  R A Maldonado; J Molina; G Payares; J A Urbina
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans.

Authors:  M Bard; N D Lees; T Turi; D Craft; L Cofrin; R Barbuch; C Koegel; J C Loper
Journal:  Lipids       Date:  1993-11       Impact factor: 1.880

6.  Cloning and disruption of the yeast C-8 sterol isomerase gene.

Authors:  W H Ashman; R J Barbuch; C E Ulbright; H W Jarrett; M Bard
Journal:  Lipids       Date:  1991-08       Impact factor: 1.880

7.  Utilization and metabolism of methyl-sterol derivatives in the yeast mutant strain GL7.

Authors:  T M Buttke; K Bloch
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

8.  Effects of sinefungin on growth and sterol composition of Leishmania promastigotes.

Authors:  P A Haughan; M L Chance; L J Goad
Journal:  Exp Parasitol       Date:  1993-09       Impact factor: 2.011

9.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala.

Authors:  T R Navin; B A Arana; F E Arana; J D Berman; J F Chajón
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

10.  Alterations induced by the antifungal compounds ketoconazole and terbinafine in Leishmania.

Authors:  M A Vannier-Santos; J A Urbina; A Martiny; A Neves; W de Souza
Journal:  J Eukaryot Microbiol       Date:  1995 Jul-Aug       Impact factor: 3.346

View more
  15 in total

Review 1.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.

Authors:  A E Paniz Mondolfi; C Stavropoulos; T Gelanew; E Loucas; A M Perez Alvarez; G Benaim; B Polsky; G Schoenian; E M Sordillo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

4.  Specificity and mode of action of the antifungal fatty acid cis-9-heptadecenoic acid produced by Pseudozyma flocculosa.

Authors:  T J Avis; R R Bélanger
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

5.  Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis.

Authors:  Juliany C F Rodrigues; Márcia Attias; Carlos Rodriguez; Julio A Urbina; Wanderley de Souza
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Clinical, morphological, and molecular characterization of Penicillium canis sp. nov., isolated from a dog with osteomyelitis.

Authors:  Daniel K Langlois; Deanna A Sutton; Cheryl L Swenson; Chris J Bailey; Nathan P Wiederhold; Nathan C Nelson; Elizabeth H Thompson; Brian L Wickes; Stephanie French; Jianmin Fu; Paulo Vilar-Saavedra; Stephen W Peterson
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

7.  An enhanced method for the identification of Leishmania spp. using real-time polymerase chain reaction and sequence analysis of the 7SL RNA gene region.

Authors:  Lindsay G Stevenson; Daniel P Fedorko; Adrian M Zelazny
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

8.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

9.  Aerobic kinetoplastid flagellate Phytomonas does not require heme for viability.

Authors:  Luděk Kořený; Roman Sobotka; Julie Kovářová; Anna Gnipová; Pavel Flegontov; Anton Horváth; Miroslav Oborník; Francisco J Ayala; Julius Lukeš
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

10.  Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.

Authors:  S T de Macedo-Silva; G Visbal; J A Urbina; W de Souza; J C F Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.